Cart
sales@molnova.com
Ruxolitinib S enantiomer
CAS No. 941685-37-6
Ruxolitinib S enantiomer( S-Ruxolitinib | INCB-018424 S enantiomer )
Catalog No. M16735 CAS No. 941685-37-6
The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 52 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 50MG | 105 | In Stock |
|
| 100MG | 141 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRuxolitinib S enantiomer
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor.
-
DescriptionThe chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.
-
In VitroRT-PCR Cell Line:Human small airway epithelial cells (SAECs) Concentration:10?μM Incubation Time:12 hours Result:Suppressed IFNβ-induced expression of ISG, IFIT, and IFITM.
-
In VivoAnimal Model:Female wild-type C57BL/6J or Nes-gfp27 mice with myeloproliferative neoplasms (MPNs) in peripheral blood Dosage:30 mg/kg (in 0.5% hydroxypropyl methylcellulose after solubilisation in DMSO) Administration: Oral gavage; twice per day separated 10-12 h for 8 weeks Result:Reduced haematopoietic cell expansion in MPN but it did not rescue bone marrow (BM) mesenchymal stem cells (MSCs).
-
SynonymsS-Ruxolitinib | INCB-018424 S enantiomer
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorChk2|JAK1|JAK2|JAK3|Tyk2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number941685-37-6
-
Formula Weight306.365
-
Molecular FormulaC17H18N6
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESN#CC[C@@H](C1CCCC1)N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2
-
Chemical Name1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Quintás-Cardama A, et al. Blood. 2010 Apr 15;115(15):3109-17.
2. Fridman JS, et al. J Immunol. 2010 May 1;184(9):5298-307.
3. Verstovsek S, et al. N Engl J Med. 2010 Sep 16;363(12):1117-27.
molnova catalog
related products
-
Butyzamide
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3.
-
Tofacitinib
Tofacitinib (CP-690550) is a potent, specific, orally active inhibitor of JAK3 with IC50 of 1 nM in cell-free assays; displays 20- to 100-fold less potency for JAK2 and JAK1 (IC50=20 nM and 112 nM, respectively).
-
ZM39923
ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1, also potently inhibits human tissue transglutaminase (TGM2) with IC50 of 10 nM.
